SCHEMBL3071609

SCHEMBL3071609

CC(=O)Nc1cc(NC(C)=O)cc(NC(C)=O)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.71
SMN1; SMN2 Q16637 3/20 0.59
HSD17B10 Q99714 2/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
HTT P42858 1/20 0.59
NAPRT Q6XQN6 1/20 0.59
ALDH1A1 P00352 5/20 0.58
GAA P10253 2/20 0.58
TDP1 Q9NUW8 2/20 0.58
KMT2A Q03164 5/20 0.56
MEN1 O00255 4/20 0.56
MAPT P10636 2/20 0.56
CA12 O43570 1/20 0.56
BRD4 O60885 1/20 0.56
NR1I2 O75469 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
MB P02144 1/20 0.56
CYP1A1 P04798 1/20 0.56
CA3 P07451 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8374421 0.89 LMNA (0.91) LMNASMN1; SMN2HSD17B10L3MBTL1HTT
SCHEMBL12781878 0.89 MEN1 (0.70) LMNASMN1; SMN2HSD17B10L3MBTL1HTT
SCHEMBL3791417 0.87 LMNA (0.58) LMNASMN1; SMN2HSD17B10L3MBTL1HTT
SCHEMBL11519910 0.87 ALDH1A1 (0.64) LMNASMN1; SMN2HSD17B10L3MBTL1HTT
SCHEMBL7538988 0.87 LMNA (0.58) LMNASMN1; SMN2HSD17B10L3MBTL1HTT
SCHEMBL25522846 0.87 LMNA (0.58) LMNASMN1; SMN2HSD17B10L3MBTL1HTT
SCHEMBL13414535 0.87 LMNA (0.58) LMNASMN1; SMN2HSD17B10L3MBTL1HTT
SCHEMBL8377058 0.85 LMNA (0.56) LMNASMN1; SMN2HSD17B10L3MBTL1HTT
SCHEMBL2735596 0.85 MEN1 (0.56) LMNASMN1; SMN2HSD17B10L3MBTL1HTT
SCHEMBL9807676 0.84 LMNA (1.00) LMNASMN1; SMN2HSD17B10L3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111995527-B Preparation method of insensitive explosive TATB 北京理工大学 2021-06-04 CN claimed
CN-111995527-A Novel preparation method of insensitive explosive TATB 北京理工大学 2020-11-27 CN claimed
US-20250230191-A1 PEPTIDE LIGANDS FOR BINDING TO MT1-MMP BICYCLETX LIMITED (GB) 2025-07-17 US disclosed
US-11814447-B2 Peptide ligands for binding to EphA2 Bicyclerd Limited (GB) 2023-11-14 US disclosed
US-20230340020-A1 PEPTIDE LIGANDS FOR BINDING TO MT1-MMP BICYCLETX LIMITED (GB) 2023-10-26 US disclosed
US-11730819-B2 Peptide derivatives having novel linkage structures BICYCLETX LIMITED (GB) 2023-08-22 US disclosed
US-20220194983-A1 PEPTIDE LIGANDS FOR BINDING TO PSMA BICYCLETX LIMITED (GB) 2022-06-23 US disclosed
CN-111995527-B Preparation method of insensitive explosive TATB 北京理工大学 2021-06-04 CN disclosed
CN-111995527-A Novel preparation method of insensitive explosive TATB 北京理工大学 2020-11-27 CN disclosed
US-20200316209-A1 PEPTIDE DERIVATIVES HAVING NOVEL LINKAGE STRUCTURES BICYCLETX LIMITED (GB) 2020-10-08 US disclosed
EP-1592738-B1 RESIN COMPOSITIONS CIBA HOLDING INC (CH) 2020-07-29 EP disclosed
US-8034952-B2 Supramolecular assemblies and building blocks UNIVERSITY OF SOUTH FLORIDA (US) 2011-10-11 US disclosed
US-7790793-B2 Amide nucleating agent compositions CIBA SPECIALTY CHEM. CORP. (US) 2010-09-07 US disclosed
US-20090143596-A1 Supramolecular Assemblies and Building Blocks UNIVERSITY OF SOUTH FLORIDA (US) 2009-06-04 US disclosed
US-20070149663-A1 Resin compositions CIBA SPECIALTY CHEMICALS CORP. 2007-06-28 US disclosed
EP-1592738-A2 RESIN COMPOSITIONS Ciba SC Holding AG (CH) 2005-11-09 EP disclosed
WO-2004072168-A2 RESIN COMPOSITIONS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 2004-08-26 WO disclosed
US-4157450-A Benzene-1,3,5-tris-acetoxime and the process for making phloroglucinol therewith AKZONA INCORPORATED (US) 1979-06-05 US disclosed
US-4115451-A Benzene-1,3,5-tris-acetoxime and the process for making phloroglucinol therewith AKZONA INCORPORATED (US) 1978-09-19 US disclosed
US-4071555-A Benzene-1,3,5-tris-acetoxime and the process for making phloroglucinol therewith AKZONA INCORPORATED (US) 1978-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250230191-A1 PEPTIDE LIGANDS FOR BINDING TO MT1-MMP MMP11, MMP3, ANPEP LMNA 1966/4885SMN1; SMN2 2755/4885HSD17B10 2078/4885
US-11814447-B2 Peptide ligands for binding to EphA2 EPHA2, CD2BP2, LNPEP LMNA 3858/4885SMN1; SMN2 4784/4885HSD17B10 3395/4885
US-20230340020-A1 PEPTIDE LIGANDS FOR BINDING TO MT1-MMP MMP11, MMP3, ANPEP LMNA 1868/4885SMN1; SMN2 2726/4885HSD17B10 2215/4885
US-20200316209-A1 PEPTIDE DERIVATIVES HAVING NOVEL LINKAGE STRUCTURES DNPEP, LNPEP, SPPL2B LMNA 1239/4885SMN1; SMN2 4397/4885HSD17B10 3578/4885
US-11730819-B2 Peptide derivatives having novel linkage structures DNPEP, LNPEP, ANPEP LMNA 1105/4885SMN1; SMN2 4422/4885HSD17B10 3656/4885
US-20220194983-A1 PEPTIDE LIGANDS FOR BINDING TO PSMA DNPEP, LNPEP, ANPEP LMNA 2981/4885SMN1; SMN2 4547/4885HSD17B10 2209/4885
US-20090143596-A1 Supramolecular Assemblies and Building Blocks TERB1, TBCB, PARG LMNA 2486/4885SMN1; SMN2 3515/4885HSD17B10 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.